ReviewFrontiers in oncology2026
Metabolomics-based exploration of the pathogenesis of breast cancer-related fatigue and progress of traditional Chinese medicine intervention.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer-related fatigue is a persistent and subjective sense of tiredness caused by either the cancer itself or its treatments. This fatigue is disproportionate to recent physical activity and significantly interferes with daily life. The exact pathogenesis of Breast cancer-related fatigue remains unclear. Breast cancer cells induce metabolic abnormalities through reprogramming. This disruption in metabolic balance-particularly in various systems-may contribute to Breast cancer-related fatigue by compromising the body's overall metabolic homeostasis, all while supporting the biosynthetic demands of cancer cell proliferation. Current pharmacological treatments for cancer-related fatigue have demonstrated limited and inconsistent efficacy. These treatments are often hindered by a narrow drug target profile, high rates of adverse effects, and the complex mechanisms underlying fatigue, particularly those related to metabolic changes. Traditional Chinese medicine, with its multi-target modulation and lower toxicity, holds significant potential as long-term adjunctive or alternative treatments for Breast cancer-related fatigue. This article reviews the current understanding of the metabolic causes of Breast cancer-related fatigue and explores the role of traditional Chinese medicine interventions, offering new insights into potential targeted therapies for this condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.